Company Overview and News

0
Hong Kong shares end higher as property stocks gain

2018-08-07 theedgemarkets
(Aug 7): Hong Kong's main Hang Seng index ended firmer on Tuesday, led by gains in property stocks, after developer Country Garden said it expected upbeat first-half results. The Hang Seng China Enterprises index closed higher.
CRBJY 2313 WHGRF 1109 CRBJF 2007 SZHIF HUNGF HNP 0902 WHGLY WGHPY

6
Hong Kong stocks fall to near 7-month low as yuan's slide adds to China growth fears

2018-06-27 theedgemarkets
SHANGHAI (June 27): Hong Kong stocks slid to nearly a seven-month low on Wednesday as a sharp fall in the yuan added to worries about China's economic growth amid escalating US-China trade tensions.
0753 AICAF 2313 AIRC 2007 AIRYY SZHIF CEO

0
China stocks extend slump on trade war fears; Hong Kong up

2018-06-20 reuters
SHANGHAI, June 20 (Reuters) - China stocks fell on Wednesday, extending a rout from the previous day, as Washington and Beijing stepped up their heated exchange over tariffs that are fuelling worries of an all-out trade war.
GGDVF GGDVY 2313 SZHIF HUNGF 0914 HNP 0902 0270

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...